<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Eli Lilly on Korea Invest Insights</title><link>https://koreainvestinsights.com/tags/eli-lilly/</link><description>Recent content in Eli Lilly on Korea Invest Insights</description><generator>Hugo -- gohugo.io</generator><language>en</language><copyright>koreainvestinsights.com · @korea_invest_insights</copyright><lastBuildDate>Sun, 08 Nov 2026 19:34:52 +0900</lastBuildDate><atom:link href="https://koreainvestinsights.com/tags/eli-lilly/feed.xml" rel="self" type="application/rss+xml"/><item><title>Half of Lilly's $1.8 Billion Beat Was One-Off. The Other Half Was Real Volume, and Price Is the Next Bill</title><link>https://koreainvestinsights.com/post/lilly-q3-2026-beat-half-one-off-half-volume-price-is-next-bill-2026-11-08/</link><pubDate>Sun, 08 Nov 2026 19:29:00 +0900</pubDate><guid>https://koreainvestinsights.com/post/lilly-q3-2026-beat-half-one-off-half-volume-price-is-next-bill-2026-11-08/</guid><description>&lt;img src="https://koreainvestinsights.com/" alt="Featured image of post Half of Lilly's $1.8 Billion Beat Was One-Off. The Other Half Was Real Volume, and Price Is the Next Bill" /&gt;&lt;p&gt;Eli Lilly reported third-quarter revenue of &lt;strong&gt;$24.40 billion&lt;/strong&gt; on October 29, up 39% from a year earlier and $1.79 billion above the $22.61 billion LSEG consensus. The stock rose 6.6% that day and 3.2% the next.&lt;/p&gt;
&lt;p&gt;Then comes the catch. About &lt;strong&gt;$0.9 billion, half of the beat&lt;/strong&gt;, will not come back. A $0.41 billion Jardiance sales milestone is the last one, and the company has no milestones left. An estimated $0.49 billion adjustment to rebate and discount accruals is a one-time reversal. The CFO said the roughly $2 billion of one-time items in 2026 will not repeat in 2027.&lt;/p&gt;
&lt;p&gt;The other half is real. Medicare&amp;rsquo;s GLP-1 bridge started on July 1 and pushed Zepbound in the United States. Mounjaro kept growing outside the United States. So the question for the next year is not volume. It is price. U.S. price fell about 10% without the one-offs, and 2027 loses the one-offs while more patients move to lower-priced channels.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Our view: Lilly&amp;rsquo;s earning power lasts, but its growth rate does not. Volume is the engine, and net price per prescription is the brake. We see 2027 revenue growth of 12% to 17%, down from about 40% in 2026. That range is our estimate from the company&amp;rsquo;s fourth-quarter implied run rate, not consensus. At $1,354, the stock trades at 27 to 29 times our 2027 range for earnings per share before acquired IPR&amp;amp;D. We read that price as already assuming a second leg of growth from retatrutide and oral share after 2027. AI spending is real but not in the numbers, so we give it no value.&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;Half of the $1.79 billion beat is one-off. Without it, revenue was about $23.5 billion, up 36% on the year and 4% to 6% on the quarter (our estimate).&lt;/li&gt;
&lt;li&gt;Volume rose 53% and price fell 15%. U.S. price was down about 10% without the one-offs, and the company expects volume to offset net price again in 2027.&lt;/li&gt;
&lt;li&gt;The Medicare bridge put more than 500,000 people on a Lilly drug, and 7 in 10 new patients chose Lilly. Mounjaro outside the United States grew 11% on the quarter, and China passed $1 billion in its first year.&lt;/li&gt;
&lt;li&gt;Fourth-quarter guidance implies a lower start for 2027: revenue of $23.8 billion to $24.8 billion and a performance margin near 49.7%, 4.5 points below the third quarter.&lt;/li&gt;
&lt;li&gt;The pipeline covers every tier of obesity treatment, but oral Foundayo sells a quarter or less of Novo&amp;rsquo;s Wegovy pill. AI has no measured result yet.&lt;/li&gt;
&lt;/ul&gt;
&lt;h2 id="weighing-the-beat-half-of-179-billion-will-not-come-back"&gt;Weighing the beat: half of $1.79 billion will not come back
&lt;/h2&gt;&lt;p&gt;&lt;img alt="Weighing the beat. Third-quarter 2026 revenue from consensus to reported, $ billion, axis starting at 20. LSEG consensus 22.61, Jardiance milestone plus 0.41, rebate and discount adjustment estimate plus 0.49, underlying sales plus 0.89, reported 24.40. The one-off items of about 0.9 are half of the 1.79 beat." loading="lazy" sizes="(max-width: 767px) calc(100vw - 30px), (max-width: 1023px) 700px, (max-width: 1279px) 950px, 1232px" src="https://koreainvestinsights.com/post-assets/lilly-q3-2026-beat-half-one-off-half-volume-price-is-next-bill-2026-11-08/beat.en.svg"&gt;
&lt;/p&gt;
&lt;p&gt;We split the beat by how long each piece lasts. The $0.89 billion we call underlying sales is the remainder after the two one-offs, so it is our derivation.&lt;/p&gt;
&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Piece&lt;/th&gt;
 &lt;th&gt;Size&lt;/th&gt;
 &lt;th&gt;Does it last?&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;Jardiance sales milestone&lt;/td&gt;
 &lt;td&gt;$0.41B&lt;/td&gt;
 &lt;td&gt;No. The 10-Q shows no milestones remaining&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Rebate and discount adjustment (est.)&lt;/td&gt;
 &lt;td&gt;about $0.49B, mostly U.S. Mounjaro&lt;/td&gt;
 &lt;td&gt;No. The CFO said the roughly $2B of 2026 one-offs does not repeat in 2027&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Medicare bridge (from July 1)&lt;/td&gt;
 &lt;td&gt;U.S. Zepbound +$0.39B on the quarter&lt;/td&gt;
 &lt;td&gt;Through the end of 2027. More than 500,000 people, 7 in 10 new patients chose Lilly, about 75% injectables, about 80% new to treatment&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Mounjaro outside the U.S.&lt;/td&gt;
 &lt;td&gt;+$0.57B on the quarter (+11%)&lt;/td&gt;
 &lt;td&gt;Continues but slows. China passed $1B in its first year on the national reimbursement list&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Operating leverage&lt;/td&gt;
 &lt;td&gt;Performance margin 54.2% (+5.9 points)&lt;/td&gt;
 &lt;td&gt;Only partly. Back-solved from guidance, the fourth quarter is about 49.7%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Foundayo (oral)&lt;/td&gt;
 &lt;td&gt;$0.184B against $0.229B expected&lt;/td&gt;
 &lt;td&gt;Unclear. A quarter or less of Novo&amp;rsquo;s Wegovy pill&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;Without the one-offs, third-quarter revenue is about $23.5 billion. That is up 36% on the year, after we also remove a $0.2 billion Jardiance milestone and a $0.18 billion Cialis rights sale from last year&amp;rsquo;s base. It is up 4% to 6% on the quarter. The quarterly figure is our estimate, because the second quarter had its own adjustments of unknown size.&lt;/p&gt;
&lt;p&gt;Product-level consensus (StreetAccount, secondary) shows where the beat landed.&lt;/p&gt;
&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Product&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Beat versus consensus&lt;/th&gt;
 &lt;th&gt;Reading&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;Mounjaro&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+$0.62B&lt;/td&gt;
 &lt;td&gt;About +$0.1B to 0.2B once the roughly $0.49B adjustment is removed&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Zepbound&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+$0.26B&lt;/td&gt;
 &lt;td&gt;First Medicare bridge quarter&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Foundayo&lt;/td&gt;
 &lt;td style="text-align: right"&gt;−$0.045B&lt;/td&gt;
 &lt;td&gt;$0.184B against $0.229B&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;All other products&lt;/td&gt;
 &lt;td style="text-align: right"&gt;about +$0.95B&lt;/td&gt;
 &lt;td&gt;Includes the $0.41B milestone. We found no product-level consensus&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;About two thirds of the earnings-per-share beat is also one-off. Moving $0.9 billion of one-off revenue almost straight to profit, at a 19% to 20% tax rate, is about $0.81 a share. That is 66% of the $1.22 gap to LSEG&amp;rsquo;s $6.26. The rest is operating leverage: revenue rose 39% while research and development rose 23% and selling and administrative cost rose 14%, and the performance margin went from 48.3% to 54.2%.&lt;/p&gt;
&lt;p&gt;We do not use the EPS surprise itself. Reported EPS was $7.22 and non-GAAP EPS was $7.48, which includes $4.57 a share of acquired IPR&amp;amp;D. Without IPR&amp;amp;D, EPS was $12.05, up 56% from $7.73. Consensus EPS ranged from $5.38 to $7.11 across data providers. They appear to treat the $2.61 billion IPR&amp;amp;D charge from the AtaiBeckley deal differently, which is our reading and not confirmed.&lt;/p&gt;
&lt;p&gt;One more detail. The non-GAAP gross margin was 84.4%, up 0.8 points on the year but 1.9 points below the second quarter&amp;rsquo;s 86.3%, in a quarter that carried $0.9 billion of one-offs. We read that as price cuts in low-priced Zepbound channels and in China outrunning cost gains. It is an estimate, because the company gives no quarterly cost split.&lt;/p&gt;
&lt;h2 id="volume-up-53-price-down-15-the-trade-behind-the-quarter"&gt;Volume up 53%, price down 15%: the trade behind the quarter
&lt;/h2&gt;&lt;p&gt;&lt;img alt="Volume up 53%, price down 15%. Third-quarter 2026 revenue growth, year on year. Total: volume plus 53%, price minus 15%, revenue plus 39%. United States: volume plus 41%, price minus 7%, revenue plus 34%. Outside the U.S.: volume plus 76%, price minus 29%, revenue plus 47%. U.S. price is about minus 10% without the one-off rebate adjustment." loading="lazy" sizes="(max-width: 767px) calc(100vw - 30px), (max-width: 1023px) 700px, (max-width: 1279px) 950px, 1232px" src="https://koreainvestinsights.com/post-assets/lilly-q3-2026-beat-half-one-off-half-volume-price-is-next-bill-2026-11-08/volprice.en.svg"&gt;
&lt;/p&gt;
&lt;p&gt;Revenue rose 39% because volume rose 53% and price fell 15%. In the United States revenue was $15.14 billion (+34%), with volume up 41% and price down 7%. The one-off rebate adjustment flatters that price. Without it, U.S. price fell about 10%, as the company said on the call. Outside the United States revenue was $9.26 billion (+47%), with volume up 76% and price down 29%.&lt;/p&gt;
&lt;p&gt;On the call the CFO said that, as in earlier years, volume should more than offset net price in 2027. A Lilly executive added that more Medicare, Medicaid and self-pay patients will push the mix toward lower-priced channels. These are two separate remarks, and the second is the one that matters for 2027.&lt;/p&gt;
&lt;h2 id="two-engines-carry-the-company"&gt;Two engines carry the company
&lt;/h2&gt;&lt;p&gt;&lt;img alt="Tirzepatide is now two thirds of the company. Quarterly tirzepatide revenue by product and region, $ million. 3Q25 10,103 (57.4% of revenue), 4Q25 11,670 (60.5%), 1Q26 12,822 (64.8%), 2Q26 14,871 (64.7%), 3Q26 16,076 (65.9%), up 8.1% on the quarter and 59% on the year." loading="lazy" sizes="(max-width: 767px) calc(100vw - 30px), (max-width: 1023px) 700px, (max-width: 1279px) 950px, 1232px" src="https://koreainvestinsights.com/post-assets/lilly-q3-2026-beat-half-one-off-half-volume-price-is-next-bill-2026-11-08/tirz.en.svg"&gt;
&lt;/p&gt;
&lt;p&gt;Tirzepatide, sold as Mounjaro and Zepbound, is 65.9% of revenue, up from 57.4% a year ago. Together with Jardiance it explains almost all of the growth.&lt;/p&gt;
&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;$ million&lt;/th&gt;
 &lt;th style="text-align: right"&gt;3Q25&lt;/th&gt;
 &lt;th style="text-align: right"&gt;4Q25&lt;/th&gt;
 &lt;th style="text-align: right"&gt;1Q26&lt;/th&gt;
 &lt;th style="text-align: right"&gt;2Q26&lt;/th&gt;
 &lt;th style="text-align: right"&gt;3Q26&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Quarter&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Year&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;Mounjaro, U.S.&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3,550&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4,143&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4,232&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4,791&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4,998&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+4.3%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+40.8%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Mounjaro, outside U.S.&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2,965&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3,267&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4,430&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5,152&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5,725&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+11.1%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+93.1%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Zepbound, U.S.&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3,568&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4,230&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4,134&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4,873&lt;/td&gt;
 &lt;td style="text-align: right"&gt;5,267&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+8.1%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+47.6%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Tirzepatide total&lt;/td&gt;
 &lt;td style="text-align: right"&gt;10,103&lt;/td&gt;
 &lt;td style="text-align: right"&gt;11,670&lt;/td&gt;
 &lt;td style="text-align: right"&gt;12,822&lt;/td&gt;
 &lt;td style="text-align: right"&gt;14,871&lt;/td&gt;
 &lt;td style="text-align: right"&gt;16,076&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+8.1%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+59.1%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Jardiance&lt;/td&gt;
 &lt;td style="text-align: right"&gt;959&lt;/td&gt;
 &lt;td style="text-align: right"&gt;768&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,114&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,231&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,577&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+28.1%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+64.4%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Trulicity&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,052&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,037&lt;/td&gt;
 &lt;td style="text-align: right"&gt;918&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,220&lt;/td&gt;
 &lt;td style="text-align: right"&gt;903&lt;/td&gt;
 &lt;td style="text-align: right"&gt;−26.0%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;−14.2%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Verzenio&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,470&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,605&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,302&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,474&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,511&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+2.5%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+2.8%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Taltz&lt;/td&gt;
 &lt;td style="text-align: right"&gt;901&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1,052&lt;/td&gt;
 &lt;td style="text-align: right"&gt;732&lt;/td&gt;
 &lt;td style="text-align: right"&gt;856&lt;/td&gt;
 &lt;td style="text-align: right"&gt;855&lt;/td&gt;
 &lt;td style="text-align: right"&gt;−0.1%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;−5.1%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Revenue&lt;/td&gt;
 &lt;td style="text-align: right"&gt;17,601&lt;/td&gt;
 &lt;td style="text-align: right"&gt;19,292&lt;/td&gt;
 &lt;td style="text-align: right"&gt;19,799&lt;/td&gt;
 &lt;td style="text-align: right"&gt;22,974&lt;/td&gt;
 &lt;td style="text-align: right"&gt;24,397&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+6.2%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+38.6%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Tirzepatide share&lt;/td&gt;
 &lt;td style="text-align: right"&gt;57.4%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;60.5%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;64.8%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;64.7%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;65.9%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;&lt;/td&gt;
 &lt;td style="text-align: right"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;img alt="Take out the two engines and little grew. Revenue by group, 3Q25 versus 3Q26, $ billion. Tirzepatide 10.10 to 16.08 (plus 59%). Jardiance 0.96 to 1.58 (plus 64%). Everything else 6.54 to 6.74 (plus 3%)." loading="lazy" sizes="(max-width: 767px) calc(100vw - 30px), (max-width: 1023px) 700px, (max-width: 1279px) 950px, 1232px" src="https://koreainvestinsights.com/post-assets/lilly-q3-2026-beat-half-one-off-half-volume-price-is-next-bill-2026-11-08/other.en.svg"&gt;
&lt;/p&gt;
&lt;p&gt;Revenue without tirzepatide and Jardiance grew only 3.1%, from $6.54 billion to $6.74 billion. It grew 6.1% if we also remove last year&amp;rsquo;s $0.18 billion Cialis rights sale. New immunology, oncology and neuroscience drugs doubled, but Trulicity (−14%) and Taltz (−5%) cancelled most of that.&lt;/p&gt;
&lt;p&gt;U.S. Mounjaro grew 4.3% on the quarter, and that includes the rebate adjustment. The company does not split the adjustment by product, so we read the underlying U.S. Mounjaro trend as close to flat. That is an estimate. U.S. growth is now Zepbound&amp;rsquo;s job, through Medicare and self-pay patients.&lt;/p&gt;
&lt;h2 id="what-lasts-and-what-does-not"&gt;What lasts and what does not
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Driver&lt;/th&gt;
 &lt;th&gt;Contribution in 3Q&lt;/th&gt;
 &lt;th&gt;Verdict&lt;/th&gt;
 &lt;th&gt;What would flip it&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;Jardiance milestone&lt;/td&gt;
 &lt;td&gt;$0.41B&lt;/td&gt;
 &lt;td&gt;Does not last&lt;/td&gt;
 &lt;td&gt;Nothing: no milestones remain&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Rebate and discount adjustment&lt;/td&gt;
 &lt;td&gt;about $0.49B&lt;/td&gt;
 &lt;td&gt;Does not last&lt;/td&gt;
 &lt;td&gt;If it repeats in the fourth quarter, accruals were conservative, but we would not count it as earnings power&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;U.S. volume from the Medicare bridge&lt;/td&gt;
 &lt;td&gt;Zepbound +$0.39B on the quarter&lt;/td&gt;
 &lt;td&gt;Lasts through 2027&lt;/td&gt;
 &lt;td&gt;New inflow slows after the first rush, or long-term Medicare coverage after 2027 stays undecided&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;U.S. volume from employers and self-pay&lt;/td&gt;
 &lt;td&gt;Not disclosed&lt;/td&gt;
 &lt;td&gt;Holds&lt;/td&gt;
 &lt;td&gt;Employers drop coverage in larger numbers&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Volume outside the U.S.&lt;/td&gt;
 &lt;td&gt;Mounjaro +$0.57B on the quarter&lt;/td&gt;
 &lt;td&gt;Lasts, but slows&lt;/td&gt;
 &lt;td&gt;Markets with high penetration, like the UK, slow. Generic semaglutide in India, Brazil and Canada&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Price&lt;/td&gt;
 &lt;td&gt;Total −15%, U.S. −10%, outside U.S. −29%&lt;/td&gt;
 &lt;td&gt;Keeps falling&lt;/td&gt;
 &lt;td&gt;Commercial insurance share rises again and narrows the fall&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Operating leverage&lt;/td&gt;
 &lt;td&gt;Performance margin +5.9 points&lt;/td&gt;
 &lt;td&gt;Partly lasts&lt;/td&gt;
 &lt;td&gt;Price cuts outrun cost savings&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Foundayo&lt;/td&gt;
 &lt;td&gt;$0.184B&lt;/td&gt;
 &lt;td&gt;Unclear&lt;/td&gt;
 &lt;td&gt;U.S. type 2 diabetes decision in the fourth quarter, reviews in more than 40 countries&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;New immunology, oncology, neuroscience drugs&lt;/td&gt;
 &lt;td&gt;$0.81B, +100%&lt;/td&gt;
 &lt;td&gt;Lasts, small&lt;/td&gt;
 &lt;td&gt;Early breast cancer interim analysis for Inluriyo in 2027&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;Volume lasts, and price and one-offs do not. The variable that decides the rest is net price per U.S. prescription. Nine-month U.S. price fell 5% including the one-offs, and 3Q fell about 10% without them. An analyst on the call described the 2026 decline as mid-teens. In 2027 Medicare (a reported $245 a month agreement, secondary) and self-pay patients, who bring lower net price per prescription, take a larger share. Net price per prescription falls further. Whether volume growth stays well above that fall sets 2027 growth.&lt;/p&gt;
&lt;p&gt;Two cautions on volume. The 500,000 Medicare patients include pent-up demand, which the company itself called a &amp;ldquo;first bolus.&amp;rdquo; And inventory rose $4.45 billion in nine months, to $18.19 billion. Launch preparation for retatrutide and Foundayo explains most of it, with work in process at $10.69 billion. But if prescription growth bends in the fourth and first quarters, part of the third-quarter volume was ahead of real demand.&lt;/p&gt;
&lt;h2 id="the-fourth-quarter-guide-starts-2027-lower"&gt;The fourth-quarter guide starts 2027 lower
&lt;/h2&gt;&lt;p&gt;&lt;img alt="The guide hides a lower starting point. Left: revenue in $ billion, axis starting at 20. Third quarter reported 24.40, third quarter without one-offs 23.50, fourth quarter implied by guidance 23.8 to 24.8. Right: performance margin in percent, axis starting at 40. Third quarter 54.2, full-year 2026 guide 52.0 to 52.5, fourth quarter implied 49.7." loading="lazy" sizes="(max-width: 767px) calc(100vw - 30px), (max-width: 1023px) 700px, (max-width: 1279px) 950px, 1232px" src="https://koreainvestinsights.com/post-assets/lilly-q3-2026-beat-half-one-off-half-volume-price-is-next-bill-2026-11-08/fourthq.en.svg"&gt;
&lt;/p&gt;
&lt;p&gt;Lilly raised its 2026 revenue guide for the third time, from $85 billion to $87 billion to $91 billion to $92 billion. The first guide in February was $80 billion to $83 billion, so the midpoint is up $10 billion. Performance margin guidance rose from 49.0% to 50.5% to 52.0% to 52.5%. Non-GAAP EPS guidance moved from $35.50 to $36.50 to $35.00 to $36.00: underlying business added $4.07 and acquired IPR&amp;amp;D took away $4.57.&lt;/p&gt;
&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Item&lt;/th&gt;
 &lt;th&gt;Fourth quarter implied&lt;/th&gt;
 &lt;th&gt;Arithmetic&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;Revenue&lt;/td&gt;
 &lt;td&gt;$23.83B to $24.83B (middle $24.33B). +24% to 29% on the year, +1% to 6% on the third-quarter underlying $23.5B&lt;/td&gt;
 &lt;td&gt;$91.0B to $92.0B less nine-month revenue of $67.17B&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Performance margin&lt;/td&gt;
 &lt;td&gt;about 49.7% (guide range 48.7% to 50.7%)&lt;/td&gt;
 &lt;td&gt;52.0% to 52.5% of full-year revenue less the nine-month figure of $35.71B&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Non-GAAP EPS&lt;/td&gt;
 &lt;td&gt;$10.59 to $11.59. IPR&amp;amp;D after September 30 is excluded from the guide&lt;/td&gt;
 &lt;td&gt;$35.00 to $36.00 less nine-month EPS of $24.41&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;The implied fourth-quarter margin is 4.5 points below the third quarter. We read it as the one-offs disappearing, seasonal costs and launch preparation spending. We also read it as the company setting a low starting point for 2027.&lt;/p&gt;
&lt;p&gt;We also share new analyses on Telegram as they are published. You are welcome to join us at &lt;a class="link" href="https://t.me/korea_invest_insights" target="_blank" rel="noopener"
 &gt;@korea_invest_insights&lt;/a&gt;.&lt;/p&gt;
&lt;h2 id="2027-growth-falls-to-the-teens-and-the-price-asks-for-more"&gt;2027: growth falls to the teens, and the price asks for more
&lt;/h2&gt;&lt;p&gt;The company gives 2027 guidance on its January call. Our table starts from the implied fourth-quarter revenue of $24.33 billion and applies a steady quarterly growth rate. It is a subjective range, not consensus.&lt;/p&gt;
&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Underlying growth per quarter&lt;/th&gt;
 &lt;th style="text-align: right"&gt;2027 revenue&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Versus 2026 reported&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Versus 2026 without $2B of one-offs&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;+2%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;$102.3B&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+11.8%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+14.3%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;+3%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;$104.8B&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+14.6%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+17.1%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;+4%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;$107.4B&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+17.4%&lt;/td&gt;
 &lt;td style="text-align: right"&gt;+20.1%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;img alt="2027 profit per share, and what $1,354 pays for it. IPR&amp;D-excluded EPS in dollars and price-to-earnings at the November 6 close. Revenue $102.0 billion: 45.1 (30.0 times), 46.9 (28.9 times), 48.8 (27.7 times) at performance margins of 50%, 52% and 54%. Revenue $105.0 billion: 46.4 (29.2 times), 48.3 (28.0 times), 50.2 (27.0 times). Revenue $108.0 billion: 47.8 (28.3 times), 49.7 (27.2 times), 51.7 (26.2 times)." loading="lazy" sizes="(max-width: 767px) calc(100vw - 30px), (max-width: 1023px) 700px, (max-width: 1279px) 950px, 1232px" src="https://koreainvestinsights.com/post-assets/lilly-q3-2026-beat-half-one-off-half-volume-price-is-next-bill-2026-11-08/heat.en.svg"&gt;
&lt;/p&gt;
&lt;p&gt;The grid assumes $1.3 billion of net other expense, a 19.5% tax rate and 888 million diluted shares. 2026 EPS before IPR&amp;amp;D is $43.6 at the guidance midpoint, and $41.8 without $2 billion of one-offs. So our 2027 range means 10% to 20% EPS growth on the underlying base.&lt;/p&gt;
&lt;p&gt;At $1,354, the stock trades at 27 to 29 times 2027 EPS of $46 to $50. Lilly expensed $8.12 a share of IPR&amp;amp;D in 2026, and business development took 96% of free cash flow. If we treat IPR&amp;amp;D as a recurring cost of about $5 a share, the multiple becomes 30 to 33 times. Growth of 10% to 20% in 2027 alone does not explain that multiple. The price assumes retatrutide and oral share lift growth again after 2027.&lt;/p&gt;
&lt;p&gt;&lt;img alt="Where the cash went, first nine months of 2026, $ billion. Operating cash flow 27.42, capital expenditure minus 8.44, free cash flow 18.98, business development cash 18.20, dividends and buybacks 8.97, rise in gross borrowings 7.0. Business development took 96% of free cash flow." loading="lazy" sizes="(max-width: 767px) calc(100vw - 30px), (max-width: 1023px) 700px, (max-width: 1279px) 950px, 1232px" src="https://koreainvestinsights.com/post-assets/lilly-q3-2026-beat-half-one-off-half-volume-price-is-next-bill-2026-11-08/cash.en.svg"&gt;
&lt;/p&gt;
&lt;p&gt;Capital spending rose 59% to $8.44 billion, and gross borrowings rose from $42.5 billion at the start of the year to $49.5 billion. The chart shows that uses of cash ($27.17 billion) exceeded free cash flow by about $8.2 billion. We did not check cash balances, so the borrowing is a match in size, not a proven funding source.&lt;/p&gt;
&lt;p&gt;The share price was $1,288.30 on October 28 and $1,373.70 on October 29 (+6.6%). It was $1,417.54 on October 30 (+3.2%), $1,364.73 on November 5 (−3.8%) and $1,354.00 on November 6, 5.1% above the pre-earnings close. We could not find the cause of the November 5 drop. Novo&amp;rsquo;s ADR fell 4.5% the same day.&lt;/p&gt;
&lt;h2 id="pipeline-the-only-full-stack-obesity-franchise-with-an-oral-hole"&gt;Pipeline: the only full-stack obesity franchise, with an oral hole
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Tier&lt;/th&gt;
 &lt;th&gt;Asset&lt;/th&gt;
 &lt;th&gt;Status&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;Standard injectable&lt;/td&gt;
 &lt;td&gt;Tirzepatide (Mounjaro, Zepbound)&lt;/td&gt;
 &lt;td&gt;U.S. compound patent to 2036, data protection to 2027. FDA approval to reduce cardiovascular risk in type 2 diabetes&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Oral entry&lt;/td&gt;
 &lt;td&gt;Foundayo (orforglipron)&lt;/td&gt;
 &lt;td&gt;U.S. obesity approval in 1Q26, U.S. launch in 2Q. U.S. type 2 diabetes decision in 4Q. Positive EU committee opinion for obesity and diabetes&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;High efficacy&lt;/td&gt;
 &lt;td&gt;Retatrutide (GIP, GLP-1 and glucagon)&lt;/td&gt;
 &lt;td&gt;TRIUMPH-1 at 80 weeks: −28.3% on 12 mg (efficacy estimand). U.S. filing in 1Q27&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Combination and next generation&lt;/td&gt;
 &lt;td&gt;Eloralintide (amylin)&lt;/td&gt;
 &lt;td&gt;Four phase 3 trials started. The EloraTZP combination (eloralintide with tirzepatide, our reading of the name) showed −23.3% at 48 weeks in phase 2 (obesity with diabetes), with phase 3 starting in 4Q26&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Maintenance&lt;/td&gt;
 &lt;td&gt;Retatrutide 4 mg&lt;/td&gt;
 &lt;td&gt;−19.0% after one dose step up in TRIUMPH-1&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;img alt="Retatrutide: the only 25%+ weight loss we found in phase 3. TRIUMPH-1, 80 weeks, mean weight change. 12 mg efficacy estimand minus 28.3%, 12 mg treatment-regimen estimand minus 25.0%, 4 mg minus 19.0%, placebo minus 2.2% and minus 3.9%. Stopping because of adverse events 11.3% versus 4.9% on placebo, paresthesia 12.5%." loading="lazy" sizes="(max-width: 767px) calc(100vw - 30px), (max-width: 1023px) 700px, (max-width: 1279px) 950px, 1232px" src="https://koreainvestinsights.com/post-assets/lilly-q3-2026-beat-half-one-off-half-volume-price-is-next-bill-2026-11-08/ret.en.svg"&gt;
&lt;/p&gt;
&lt;p&gt;The TRIUMPH-1 figures come from Lilly&amp;rsquo;s own release. In type 2 diabetes, Lilly&amp;rsquo;s earlier data (second-quarter 8-K) showed A1C down 2.2% against 1.8% for semaglutide 2 mg, and weight down 20% to 21% against 9.4%. Novo has an oral drug, a higher-dose Wegovy (7.2 mg) and a combination (CagriSema, with a U.S. launch in early 2027 per its 6-K). But the only asset in our research that showed weight loss of 25% or more in phase 3 is retatrutide. We read that efficacy gap as the reason Lilly can hold high-efficacy pricing in the United States after 2028. That is our view.&lt;/p&gt;
&lt;p&gt;The weaknesses are as concrete as the strengths.&lt;/p&gt;
&lt;p&gt;&lt;img alt="The oral race: Lilly is behind. Left: third-quarter sales in $ billion. Novo’s Wegovy pill 0.79 to 0.87, Lilly’s Foundayo 0.18. Right: weekly prescriptions in early September (press, IQVIA). Wegovy pill about 181,000, Foundayo about 44,000." loading="lazy" sizes="(max-width: 767px) calc(100vw - 30px), (max-width: 1023px) 700px, (max-width: 1279px) 950px, 1232px" src="https://koreainvestinsights.com/post-assets/lilly-q3-2026-beat-half-one-off-half-volume-price-is-next-bill-2026-11-08/oral.en.svg"&gt;
&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;strong&gt;The oral launch lags.&lt;/strong&gt; Novo&amp;rsquo;s Wegovy pill had third-quarter sales of DKK 5.394 billion, about $0.79 billion to $0.87 billion, which is 4.3 to 4.7 times Foundayo&amp;rsquo;s $0.184 billion. Lilly&amp;rsquo;s &amp;ldquo;about 40% of new oral patients&amp;rdquo; counts new patients only. Cumulative prescriptions favor Novo.&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Little diversification outside incretins.&lt;/strong&gt; New drugs are 3.3% of revenue. Government-set prices under the Inflation Reduction Act apply to Trulicity and Verzenio from 2028 and to Jardiance from 2026. Taltz has U.S. data protection to 2028 and a compound patent to 2030.&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;The tirzepatide price clock starts before the patent ends.&lt;/strong&gt; Under the rule in the 10-Q, a new-drug-application medicine faces government price nine years after approval. For Mounjaro (approved in 2022) that is around 2031, our estimate, five years before the 2036 patent.&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;Bought assets are mostly phase 1 and 2.&lt;/strong&gt; Nine-month business development cash was $18.2 billion. Deals include Centessa (orexin, $5.96 billion net cash), Kelonia (in-body CAR-T, $3.09 billion), AtaiBeckley (depression, $2.61 billion of IPR&amp;amp;D), Orna (in-body CAR-T, $1.23 billion), Ventyx (NLRP3, $1.06 billion), Curevo (shingles vaccine, $0.95 billion) and Ajax (JAK2, $0.91 billion). In October Lilly added an autoimmune deal worth up to $2.9 billion. Their value shows up in numbers after 2029. The business development head said Lilly does not need near-term revenue and can take calculated risks.&lt;/li&gt;
&lt;li&gt;&lt;strong&gt;New launches have little pricing room.&lt;/strong&gt; Lilly&amp;rsquo;s voluntary agreement with the U.S. government says new drugs launch at a price balanced across developed countries. The CEO said Lilly will narrow the gap between U.S. and non-U.S. prices for obesity drugs. Retatrutide will find it hard to launch at the high price of past U.S. launches.&lt;/li&gt;
&lt;/ul&gt;
&lt;h2 id="ai-real-spending-no-numbers-yet"&gt;AI: real spending, no numbers yet
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Area&lt;/th&gt;
 &lt;th&gt;What is public&lt;/th&gt;
 &lt;th&gt;Source level&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;Computing&lt;/td&gt;
 &lt;td&gt;LillyPod: NVIDIA DGX SuperPOD, 1,016 Blackwell Ultra GPUs, more than 9,000 petaflops, running in Indianapolis since February 2026&lt;/td&gt;
 &lt;td&gt;NVIDIA blog, February 26, 2026&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Joint lab&lt;/td&gt;
 &lt;td&gt;Up to $1 billion over five years from the two companies combined, San Francisco Bay Area, linking wet and dry labs&lt;/td&gt;
 &lt;td&gt;NVIDIA announcement, January 12, 2026. We have not confirmed it has opened&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;TuneLab&lt;/td&gt;
 &lt;td&gt;Models trained on data from more than $1 billion of Lilly research, offered to biotechs. Federated learning means raw data is not shared, only model updates. Distribution widened in 2026 through Benchling, Revvity, CDD Vault, Ginkgo, Twist and Charles River&lt;/td&gt;
 &lt;td&gt;Revvity, Ginkgo and Twist releases, others secondary. Number of participants and revenue model not disclosed&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;AI drug deals&lt;/td&gt;
 &lt;td&gt;Insilico (March 2026, $115 million upfront, up to about $2.75 billion), Profluent (April 2026, up to $2.25 billion, AI-designed recombinases), Chai Discovery, Isomorphic, Superluminal, OpenAI (antibiotics)&lt;/td&gt;
 &lt;td&gt;Some official. Amounts are headlines that include milestones&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Direct sales&lt;/td&gt;
 &lt;td&gt;LillyDirect (self-pay, linked to Walmart, Amazon Pharmacy and GoodRx). Self-pay was about 45% of Zepbound prescriptions in 2Q&lt;/td&gt;
 &lt;td&gt;Secondary&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Manufacturing&lt;/td&gt;
 &lt;td&gt;Ten new U.S. sites since 2020, a $50 billion U.S. manufacturing plan (secondary), and the third-quarter start of Houston ($6.5 billion) and Richmond ($5 billion)&lt;/td&gt;
 &lt;td&gt;Call (primary) and secondary&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;The technology that moves 2026 and 2027 profit is direct sales and manufacturing, not AI. Direct sales pull in demand without a pharmacy benefit manager but lower net price per prescription. Manufacturing capacity ended the 2022 to 2024 supply shortage, and the rise in inventory and 59% higher capital spending are building 2027 and 2028 launch volume ahead of time.&lt;/p&gt;
&lt;p&gt;AI is not in the numbers yet. We found no AI, NVIDIA or TuneLab remarks in the third-quarter call transcript. Lilly has not disclosed the number of clinical assets that came from AI, the development time saved or the cost savings.&lt;/p&gt;
&lt;p&gt;The direction of the edge is still clear. Lilly&amp;rsquo;s difference is its ecosystem more than its GPU count. Roche has more GPUs (more than 3,500, secondary). Lilly uses TuneLab&amp;rsquo;s federated learning so that biotechs&amp;rsquo; data grows Lilly&amp;rsquo;s models, and then links those biotechs to Lilly through Gateway Labs, equity stakes and acquisitions. It is the same structure as the business development advantage the head of that team described on the call. We expect the value to show up first in sourcing assets and later in research productivity. That is our view. For now we give AI no value in the investment judgment. If the December 7 Innovation Day brings a measured metric, such as the number of AI-derived assets or shorter cycle times, we will look again.&lt;/p&gt;
&lt;h2 id="what-it-means-for-novo-and-for-korea"&gt;What it means for Novo and for Korea
&lt;/h2&gt;&lt;p&gt;Novo&amp;rsquo;s Wegovy pill leads the oral tier, but Novo guides 2026 adjusted sales growth at −2% to +2% at constant exchange rates (6-K). The oral lead has not yet turned into total growth. Lilly&amp;rsquo;s edge rests on injectable efficacy and manufacturing capacity.&lt;/p&gt;
&lt;p&gt;For Korea, our earlier note on Lilly&amp;rsquo;s third quarter from the Korean biotech side found a narrow path from Lilly&amp;rsquo;s results to Korean listed biotechs. This quarter does not change that. Lilly described its non-U.S. pricing as disciplined and as narrowing the gap with the United States, so we see no new case for a lower price of Mounjaro in Korea.&lt;/p&gt;
&lt;h2 id="what-would-change-our-reading"&gt;What would change our reading
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;January call outcome&lt;/th&gt;
 &lt;th&gt;Test&lt;/th&gt;
 &lt;th&gt;What it would mean&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;Base&lt;/td&gt;
 &lt;td&gt;2027 revenue guide midpoint of $101B to $106B, performance margin of 49% to 53%&lt;/td&gt;
 &lt;td&gt;Volume offsets price and growth is in the teens. Our reading holds&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Up&lt;/td&gt;
 &lt;td&gt;Midpoint above $106B and performance margin of 52% or more&lt;/td&gt;
 &lt;td&gt;Volume strength beats the fall in price. The top of our EPS range&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Down&lt;/td&gt;
 &lt;td&gt;Midpoint below $101B, or a warned U.S. net price decline of 15% or more&lt;/td&gt;
 &lt;td&gt;Price dominates. The case for a 27 to 29 times multiple weakens&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;We will look at our reading again if the midpoint of the 2027 revenue guide is below $101 billion, or if Lilly warns of a U.S. net price decline of 15% or more.&lt;/p&gt;
&lt;p&gt;&lt;img alt="What to check next. December 7, 2026: Lilly Innovation Day. Fourth quarter 2026: Foundayo U.S. type 2 diabetes decision and EU decision. Weekly: Foundayo and Wegovy pill prescriptions. January 2027: fourth-quarter results and 2027 guidance. First quarter 2027: retatrutide U.S. filing. Early 2027: Novo’s CagriSema U.S. launch. December 31, 2027: the Medicare bridge ends." loading="lazy" sizes="(max-width: 767px) calc(100vw - 30px), (max-width: 1023px) 700px, (max-width: 1279px) 950px, 1232px" src="https://koreainvestinsights.com/post-assets/lilly-q3-2026-beat-half-one-off-half-volume-price-is-next-bill-2026-11-08/calendar.en.svg"&gt;
&lt;/p&gt;
&lt;p&gt;The December 7 event can show the first measurable AI metric and the retatrutide filing plan. The January call is the main scorecard.&lt;/p&gt;
&lt;h2 id="data-notes"&gt;Data notes
&lt;/h2&gt;&lt;ul&gt;
&lt;li&gt;Consensus (LSEG, StreetAccount) is secondary reporting. We could not confirm whether consensus EPS includes IPR&amp;amp;D.&lt;/li&gt;
&lt;li&gt;The $0.49 billion rebate adjustment is the company&amp;rsquo;s &amp;ldquo;about $0.9 billion&amp;rdquo; less the milestone. The company did not split it by product, and our estimate for the size of the second-quarter adjustment is rough.&lt;/li&gt;
&lt;li&gt;We checked the call remarks against the Motley Fool transcript (AI-assisted) in a browser. We could not open the company&amp;rsquo;s slide deck.&lt;/li&gt;
&lt;li&gt;Foundayo&amp;rsquo;s approval date and price, weekly Wegovy pill prescriptions, the Medicare agreement price, AI deal amounts, TuneLab participants and total manufacturing investment are secondary. The retatrutide TRIUMPH-1 results and Novo&amp;rsquo;s Wegovy pill sales are primary.&lt;/li&gt;
&lt;li&gt;We could not find the cause of the 3.8% drop on November 5.&lt;/li&gt;
&lt;li&gt;Our 2027 revenue and EPS ranges are subjective estimates built from the company&amp;rsquo;s fourth-quarter implied figures. They are not consensus.&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;Sources:&lt;/p&gt;
&lt;ul&gt;
&lt;li&gt;&lt;a class="link" href="https://www.sec.gov/Archives/edgar/data/59478/000005947826000104/q326lillysalesandearningsp.htm" target="_blank" rel="noopener"
 &gt;Lilly 3Q26 8-K, exhibit 99.1&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://www.sec.gov/Archives/edgar/data/59478/000005947826000108/lly-20260930.htm" target="_blank" rel="noopener"
 &gt;Lilly 3Q26 10-Q&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm" target="_blank" rel="noopener"
 &gt;Lilly 2Q26 10-Q&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://www.sec.gov/Archives/edgar/data/59478/000005947826000045/lly-20260331.htm" target="_blank" rel="noopener"
 &gt;Lilly 1Q26 10-Q&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm" target="_blank" rel="noopener"
 &gt;Lilly 2025 10-K&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://www.sec.gov/Archives/edgar/data/59478/000005947826000008/q425lillysalesandearningsp.htm" target="_blank" rel="noopener"
 &gt;Lilly 4Q25 results&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://www.fool.com/earnings/call-transcripts/2026/10/29/eli-lilly-lly-q3-2026-earnings-call-transcript/" target="_blank" rel="noopener"
 &gt;Q3 2026 call transcript (Motley Fool)&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss" target="_blank" rel="noopener"
 &gt;Lilly TRIUMPH-1 release&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://www.sec.gov/Archives/edgar/data/353278/000162828026069805/caq32026.htm" target="_blank" rel="noopener"
 &gt;Novo Nordisk 3Q26 6-K&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://nvidianews.nvidia.com/news/nvidia-and-lilly-announce-co-innovation-lab-to-reinvent-drug-discovery-in-the-age-of-ai" target="_blank" rel="noopener"
 &gt;NVIDIA and Lilly co-innovation lab&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://blogs.nvidia.com/blog/2026/02/26/lilly-ai-factory-live/" target="_blank" rel="noopener"
 &gt;NVIDIA on LillyPod going live&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://ir.revvity.com/news/investor-news/news-details/2026/Revvity-Collaborates-with-Lilly-to-Expand-Access-to-AI-Drug-Discovery-Models/" target="_blank" rel="noopener"
 &gt;Revvity and Lilly on AI drug discovery models&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://www.profluent.bio/media/profluent-announces-strategic-partnership-with-eli-lilly-to-develop-ai-designed-recombinases-for-genetic-medicine" target="_blank" rel="noopener"
 &gt;Profluent and Lilly partnership&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://www.eurekalert.org/news-releases/1121866" target="_blank" rel="noopener"
 &gt;EurekAlert release&lt;/a&gt;&lt;/li&gt;
&lt;li&gt;&lt;a class="link" href="https://hlth.com/insights/news/eli-lilly-s-foundayo-prescriptions-rise-as-novo-nordisk-s-wegovy-pill-maintains-lead" target="_blank" rel="noopener"
 &gt;HLTH on Foundayo prescriptions&lt;/a&gt;&lt;/li&gt;
&lt;/ul&gt;
&lt;p&gt;&lt;strong&gt;Two questions for the comments.&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;1. Where will Lilly&amp;rsquo;s 2027 revenue guide land in January? A. Below $101 billion. B. $101 billion to $106 billion. C. Above $106 billion.&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;2. What is the first number you check on the January call? A. U.S. net price per prescription. B. Tirzepatide volume. C. The retatrutide filing date. D. Foundayo&amp;rsquo;s share of new oral patients.&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;This is for research and information only, not investment advice. Ranges, multiples and scenarios are analytical assumptions, not trading instructions or individual portfolio decisions. Figures are dated data. OpenAI, a competitor of Anthropic, is one of Lilly&amp;rsquo;s AI partners, and we used public material only and do not judge its effect. We used Anthropic&amp;rsquo;s Claude to help collect sources and edit this post.&lt;/p&gt;</description></item></channel></rss>